These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20425407)

  • 21. Prolonged idiotypic vaccination against follicular lymphoma.
    Inoges S; Lopez-Diaz de Cerio A; Zabalegui N; Soria E; Villanueva H; Panizo C; Rodriguez-Caballero A; Suarez L; Pastor F; Rodriguez-Calvillo M; Orfao A; Bendandi M
    Leuk Lymphoma; 2009 Jan; 50(1):47-53. PubMed ID: 19152172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Past, present and future of anti-idiotype vaccination].
    Rodríguez Calvillo M; Inogés S; López Díaz de Cerio A; Zabalegui N; Panizo C; Hernández M; Pérez Calvo J; Prósper F; Melero I; Sánchez-Ibarrola A; Rocha E; Bendandi M
    Rev Med Univ Navarra; 2004; 48(3):14-23. PubMed ID: 15622921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma.
    Hollander N
    Crit Rev Immunol; 2009; 29(5):399-418. PubMed ID: 20001888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Active immunotherapy in follicular lymphoma.
    Veelken H
    Semin Cancer Biol; 2003 Jun; 13(3):241-7. PubMed ID: 12959355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma.
    Navarrete MA; Heining-Mikesch K; Schüler F; Bertinetti-Lapatki C; Ihorst G; Keppler-Hafkemeyer A; Dölken G; Veelken H
    Blood; 2011 Feb; 117(5):1483-91. PubMed ID: 21045197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.
    Muraro E; Martorelli D; Dolcetti R
    Hum Vaccin Immunother; 2013 May; 9(5):1078-83. PubMed ID: 23406835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes.
    Baskar S; Kobrin CB; Kwak LW
    J Clin Invest; 2004 May; 113(10):1498-510. PubMed ID: 15146248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination strategies in the treatment of lymphomas.
    Veelken H; Osterroth F
    Oncology; 2002; 62(3):187-200. PubMed ID: 12065865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical results of the ID-KLH vaccination with local GM-CSF in patients with follicular lymphomas (published in Nature Med 1999; 5: 1171-1177) summary of the lecture by L. W. Kwak.
    Schumacher K
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R10-3. PubMed ID: 11768618
    [No Abstract]   [Full Text] [Related]  

  • 30. Idiotype vaccines for human B-cell malignancies.
    Inoges S; de Cerio AL; Soria E; Villanueva H; Pastor F; Bendandi M
    Curr Pharm Des; 2010 Jan; 16(3):300-7. PubMed ID: 20109139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idiotype vaccine strategies for improving outcomes in follicular lymphoma.
    Sinha R; Shenoy PJ; Flowers CR
    Expert Opin Biol Ther; 2008 Aug; 8(8):1213-23. PubMed ID: 18613772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli.
    Bertinetti C; Simon F; Zirlik K; Heining-Mikesch K; Pfeifer D; Osterroth F; Rosenthal FM; Veelken H
    Eur J Haematol; 2006 Nov; 77(5):395-402. PubMed ID: 16879605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
    Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility of idiotype vaccination in relapsed B-cell malignancies.
    Inogés S; Rodríguez-Calvillo M; López-Díaz de Cerio A; Zabalegui N; Pérez-Calvo J; Panizo C; Hernandez M; Cuesta B; Rocha E; Bendandi M
    Haematologica; 2003 Dec; 88(12):1438-40. PubMed ID: 14688006
    [No Abstract]   [Full Text] [Related]  

  • 35. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
    Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Idiotype vaccines in the treatment of follicular lymphoma: current status and future perspectives].
    Zabalegui N; López Díaz de Cerio A; Inogés S; Soria E; Villanueva H; Rivero P
    An Sist Sanit Navar; 2009; 32(1):61-73. PubMed ID: 19430512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.
    Marron TU; Ronner L; Martin PE; Flowers CR; Brody JD
    Immunotherapy; 2016 Nov; 8(11):1335-1346. PubMed ID: 27993085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccine therapy for B-cell lymphomas: next-generation strategies.
    Neelapu SS; Kwak LW
    Hematology Am Soc Hematol Educ Program; 2007; ():243-9. PubMed ID: 18024636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.
    Kafi K; Betting DJ; Yamada RE; Bacica M; Steward KK; Timmerman JM
    Mol Immunol; 2009 Jan; 46(3):448-56. PubMed ID: 19046770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status of therapeutic vaccines for non-Hodgkin's lymphoma.
    Hurvitz SA; Timmerman JM
    Curr Opin Oncol; 2005 Sep; 17(5):432-40. PubMed ID: 16093791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.